Pyxis Oncology, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Pyxis Oncology, Inc. (PYXS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $3.38 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-23
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.38M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.28M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.19M.
- 2023-02-02: Lessee, Operating Lease, Liability, to be Paid, Year One $1.50M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $3.38M 10-K · filed 2026-03-23 |
| 2024-12-31 | $3.28M 10-K · filed 2025-03-18 |
| 2023-12-31 | $3.19M 10-K · filed 2024-03-21 |
| 2023-02-02 | $1.50M 10-K · filed 2024-03-21 |
| 2022-12-31 | $2.56M 10-K · filed 2023-03-22 |
| 2022-09-30 | $3.12M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $3.12M 10-Q · filed 2022-08-15 |
| 2021-12-31 | $168.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |